A Scientometrics Analysis and Visualization of Refractory Gastroesophageal Reflux Disease

Overview

Journal Front Pharmacol

Date 2024 Aug 14

PMID 39139634

Authors

Nan Zhang

Ming Han

Qin-Wei Zheng

Meng-Yuan Zhang

Wen-Lan Zhi

Jing-Jing Li

Lin-Xuan Cui

Jin-Li Tian

Yi Wang

Sheng-Quan Fang

Affiliations

Soon will be listed here.

Abstract

Background: Refractory gastroesophageal reflux disease (refractory GERD) is a heterogeneous disease characterized by unresponsiveness or poor efficacy to proton-pump inhibitors (PPIs). This chronic disorder substantially weakens patients' mental wellbeing and quality of life, increasing the financial burden on society. Multiple articles have been reported in this area. However, literature involving scientometric analysis of refractory GERD is absent. Therefore, it is necessary to understand the evolution of research themes and the main hotspots of refractory GERD through bibliometric methods.

Methods: All documents related to refractory GERD based on the WOS Core Collection from January 2000 to November 2023 were selected for analysis. Citespace V 6.1 R6, VOSviewer V 1.6.20, and Scimago Graphica V 1.0.38 were used to perform bibliometric analysis.

Results: We collected a total of 241 research articles from 36 countries and 322 institutions, contributed by over 1,000 authors. Over the last 20 years, the number of articles in this field has increased year by year, and since 2011, the number of publications has increased dramatically, with 85.89% of the papers. These countries are led by the United States and Japan. had the highest number of citations and had the highest number of publications. Research on standardized diagnosis and management, mechanisms, novel monitoring methods, and innovative drugs and procedures for refractory GERD are the main topics and hotspots in this field. This study also found that neuroimmune interaction is closely related to refractory GERD, which may be a new direction for future mechanism research.

Conclusion: Our study is the first bibliometric analysis of the global literature on refractory GERD. This research provides valuable insights for researchers, enabling them to quickly understand the research frontier and hot topics of this field.

References

Yang X, Tan J, Liu Y, Feng Y, Shi R . Comparison of 180° anti-reflux mucosectomy versus 270° anti-reflux mucosectomy for treatment of refractory gastroesophageal reflux disease: a retrospective study. Surg Endosc. 2021; 36(7):5002-5010. PMC: 9160125. DOI: 10.1007/s00464-021-08857-5. View

Wahlqvist P, Reilly M, Barkun A . Systematic review: the impact of gastro-oesophageal reflux disease on work productivity. Aliment Pharmacol Ther. 2006; 24(2):259-72. DOI: 10.1111/j.1365-2036.2006.02996.x. View

Ustaoglu A, Woodland P . Sensory Phenotype of the Oesophageal Mucosa in Gastro-Oesophageal Reflux Disease. Int J Mol Sci. 2023; 24(3). PMC: 9917190. DOI: 10.3390/ijms24032502. View

Dallemagne B, Weerts J, Jehaes C, Markiewicz S, Lombard R . Laparoscopic Nissen fundoplication: preliminary report. Surg Laparosc Endosc. 1991; 1(3):138-43. View

Wang Y, Pan T, Wang Q, Guo Z . Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev. 2009; (4):CD004275. DOI: 10.1002/14651858.CD004275.pub3. View

Xu W, Bai Z, Shang Y, Wang J, Wong Y, Qi X . Incidence and type of adverse events in patients taking vonoprazan: A systematic review and meta-analysis. Therap Adv Gastroenterol. 2023; 16:17562848231167858. PMC: 10126681. DOI: 10.1177/17562848231167858. View

Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T . Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015; 42(6):719-30. DOI: 10.1111/apt.13325. View

Chey W, Mody R, Izat E . Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement?. Dig Dis Sci. 2010; 55(12):3415-22. DOI: 10.1007/s10620-010-1209-2. View

Yamashita H, Okada A, Naora K, Hongoh M, Kinoshita Y . Adding Acotiamide to Gastric Acid Inhibitors Is Effective for Treating Refractory Symptoms in Patients with Non-erosive Reflux Disease. Dig Dis Sci. 2018; 64(3):823-831. PMC: 6394577. DOI: 10.1007/s10620-018-5377-9. View

10.

Kahrilas P, Bredenoord A, Fox M, Gyawali C, Roman S, Smout A . The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2014; 27(2):160-74. PMC: 4308501. DOI: 10.1111/nmo.12477. View

11.

Souza R, Huo X, Mittal V, Schuler C, Carmack S, Zhang H . Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology. 2009; 137(5):1776-84. DOI: 10.1053/j.gastro.2009.07.055. View

12.

Vela M, Srinivasan R, Tutuian R, Katz P, Castell D . Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology. 2001; 120(7):1599-606. DOI: 10.1053/gast.2001.24840. View

13.

Riehl M, Kinsinger S, Kahrilas P, Pandolfino J, Keefer L . Role of a health psychologist in the management of functional esophageal complaints. Dis Esophagus. 2015; 28(5):428-36. PMC: 4703073. DOI: 10.1111/dote.12219. View

14.

Zdrhova L, Bitnar P, Balihar K, Kolar P, Madle K, Martinek M . Breathing Exercises in Gastroesophageal Reflux Disease: A Systematic Review. Dysphagia. 2022; 38(2):609-621. PMC: 9888515. DOI: 10.1007/s00455-022-10494-6. View

15.

Gupta K, Harvima I . Mast cell-neural interactions contribute to pain and itch. Immunol Rev. 2018; 282(1):168-187. PMC: 5812374. DOI: 10.1111/imr.12622. View

16.

Rohof W, Bennink R, de Jonge H, Boeckxstaens G . Increased proximal reflux in a hypersensitive esophagus might explain symptoms resistant to proton pump inhibitors in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2013; 12(10):1647-55. DOI: 10.1016/j.cgh.2013.10.026. View

17.

ALLISON P . Reflux esophagitis, sliding hiatal hernia, and the anatomy of repair. Surg Gynecol Obstet. 1951; 92(4):419-31. View

18.

Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N . Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2015; 43(2):240-51. PMC: 4738414. DOI: 10.1111/apt.13461. View

19.

Charbel S, Khandwala F, Vaezi M . The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol. 2005; 100(2):283-9. DOI: 10.1111/j.1572-0241.2005.41210.x. View

20.

Kahrilas P, Howden C, Wernersson B, Denison H, Nuevo J, Gisbert J . Impact of persistent, frequent regurgitation on quality of life in heartburn responders treated with acid suppression: a multinational primary care study. Aliment Pharmacol Ther. 2013; 37(10):1005-10. DOI: 10.1111/apt.12298. View